These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36287571)

  • 1. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
    Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
    Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
    Saller JJ; Haider M; Al-Diffalha S; Coppola D
    Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin.
    Vikeså J; Møller AK; Kaczkowski B; Borup R; Winther O; Henao R; Krogh A; Perell K; Jensen F; Daugaard G; Nielsen FC
    BMC Cancer; 2015 Mar; 15():151. PubMed ID: 25885340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
    Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
    Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
    Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
    J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.
    Ferracin M; Pedriali M; Veronese A; Zagatti B; Gafà R; Magri E; Lunardi M; Munerato G; Querzoli G; Maestri I; Ulazzi L; Nenci I; Croce CM; Lanza G; Querzoli P; Negrini M
    J Pathol; 2011 Sep; 225(1):43-53. PubMed ID: 21630269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
    Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
    Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
    Yoon HH; Foster NR; Meyers JP; Steen PD; Visscher DW; Pillai R; Prow DM; Reynolds CM; Marchello BT; Mowat RB; Mattar BI; Erlichman C; Goetz MP
    Ann Oncol; 2016 Feb; 27(2):339-44. PubMed ID: 26578722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological characterization and autopsybased classification of the Cancer of Unknown Primary origin (CUP) syndrome].
    Kocsmár É; Kocsmár I; Karczub J; Istók R; Kiss A; Schaff Z; Lotz G
    Magy Onkol; 2019 Jun; 63(2):75-84. PubMed ID: 31225530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.